Liquidia (NASDAQ:LQDA) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Liquidia (NASDAQ:LQDA) had its target price upped by analysts at Wells Fargo & Company from $23.00 to $25.00 in a report released on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective indicates a potential upside of 77.30% from the company’s current price.

A number of other research analysts have also weighed in on the company. BTIG Research reaffirmed a “buy” rating on shares of Liquidia in a report on Tuesday, May 27th. HC Wainwright lifted their price target on Liquidia from $29.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, May 28th. Wall Street Zen upgraded Liquidia from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd. Oppenheimer set a $13.00 price target on Liquidia and gave the company an “underperform” rating in a research report on Monday, May 19th. Finally, Raymond James lifted their price target on Liquidia from $27.00 to $29.00 and gave the company a “strong-buy” rating in a research report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Liquidia currently has an average rating of “Moderate Buy” and an average price target of $26.89.

Liquidia Stock Performance

Shares of LQDA opened at $14.10 on Thursday. The business has a 50-day moving average of $15.16 and a 200 day moving average of $14.13. Liquidia has a fifty-two week low of $8.26 and a fifty-two week high of $19.41. The firm has a market cap of $1.21 billion, a P/E ratio of -8.65 and a beta of 0.04.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.03). The company had revenue of $3.12 million for the quarter, compared to analysts’ expectations of $3.23 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. As a group, research analysts predict that Liquidia will post -1.51 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Rajeev Saggar sold 2,450 shares of the business’s stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $13.67, for a total value of $33,491.50. Following the completion of the sale, the insider now owns 263,152 shares in the company, valued at $3,597,287.84. The trade was a 0.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Jason Adair sold 1,856 shares of the business’s stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $25,185.92. Following the completion of the sale, the insider now owns 184,304 shares of the company’s stock, valued at $2,501,005.28. The trade was a 1.00% decrease in their position. The disclosure for this sale can be found here. Insiders sold 33,138 shares of company stock worth $450,233 in the last quarter. 26.50% of the stock is owned by insiders.

Institutional Trading of Liquidia

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Rhumbline Advisers lifted its position in Liquidia by 6.0% in the first quarter. Rhumbline Advisers now owns 85,463 shares of the company’s stock valued at $1,261,000 after purchasing an additional 4,811 shares during the last quarter. Bluefin Capital Management LLC bought a new stake in Liquidia in the first quarter valued at approximately $250,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Liquidia by 15.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock valued at $1,796,000 after purchasing an additional 16,022 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Liquidia by 10.7% in the first quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock valued at $12,703,000 after purchasing an additional 82,955 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Liquidia by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock valued at $556,000 after purchasing an additional 1,700 shares during the last quarter. Institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).